



Genome-wide association analysis identifies three new breast cancer susceptibility loci

The Harvard community has made this article openly available. [Please share](#) how this access benefits you. Your story matters

Citation	Ghoussaini, Maya, Olivia Fletcher, Kyriaki Michailidou, Clare Turnbull, Marjanka K Schmidt, Ed Dicks, Joe Dennis, et al. 2013. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature genetics 44(3): 312-318.
Published Version	doi:10.1038/ng.1049
Citable link	http://nrs.harvard.edu/urn-3:HUL.InstRepos:11370694
Terms of Use	This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Published in final edited form as:

Nat Genet. ; 44(3): 312–318. doi:10.1038/ng.1049.

Genome-wide association analysis identifies three new breast cancer susceptibility loci

Maya Ghoussaini¹, Olivia Fletcher², Kyriaki Michailidou³, Clare Turnbull⁴, Marjanka K Schmidt^{5,6}, Ed Dicks¹, Joe Dennis³, Qin Wang³, Manjeet K Humphreys³, Craig Luccarini¹, Caroline Baynes¹, Don Conroy¹, Melanie Maranian¹, Shahana Ahmed¹, Kristy Driver¹, Nichola Johnson², Nicholas Orr², Isabel dos Santos Silva⁷, Quinten Waisfisz⁸, Hanne Meijers-Heijboer⁸, Andre G. Uitterlinden⁹, Fernando Rivadeneira⁹, HEBON¹⁰, Per Hall¹¹, Kamila Czene¹¹, Astrid Irwanto¹³, Jianjun Liu¹², Heli Nevanlinna¹³, Kristiina Aittomäki¹⁴, Carl Blomqvist¹⁵, Alfons Meindl¹⁶, Rita K Schmutzler¹⁷, Bertram Müller-Myhsok¹⁸, Peter Lichtner¹⁹, Jenny Chang-Claude²⁰, Rebecca Hein^{20,21}, Stefan Nickels²⁰, Dieter Flesch-Janys^{22,23}, Helen Tsimiklis²⁴, Enes Makalic²⁵, Daniel Schmidt²⁵, Minh Bui²⁵, John L Hopper²⁵, Carmel Apicella²⁵, Daniel J Park²⁴, Melissa Southey²⁴, David J Hunter²⁶, Stephen J Chanock²⁷, Annetien Broeks⁵, Senno Verhoef²⁸, Frans BL Hogervorst²⁹, Peter A. Fasching³⁰, Michael P. Lux³⁰, Matthias W. Beckmann³⁰, Arif B. Ekici³¹, Elinor Sawyer³², Ian Tomlinson³³, Michael Kerin³⁴, Frederik Marme^{35,36}, Andreas Schneeweiss^{35,36}, Christof Sohn³⁵, Barbara Burwinkel^{35,37}, Pascal Guénel^{38,39}, Thérèse Truong^{38,39}, Emilie Cordina-Duverger^{38,39}, Florence Menegaux^{38,39}, Stig E Bojesen^{40,41}, Børge G Nordestgaard^{40,41}, Sune F Nielsen^{40,41}, Henrik Flyger⁴², Roger L. Milne⁴³, M. Rosario Alonso⁴⁴, Anna González-Neira⁴⁴, Javier Benítez⁴⁵, Hoda Anton-Culver⁴⁶, Argyrios Ziogas⁴⁶, Leslie Bernstein⁴⁷, Christina Clarke Dur⁴⁸, Hermann Brenner⁴⁹, Heiko Müller⁴⁹, Volker Arndt⁴⁹, Christa Stegmaier⁵⁰, FBCS⁴, Christina Justenhoven^{51,52}, Hiltrud Brauch^{51,52}, Thomas Brüning⁵³, The GENICA Network^{51,52,53,54,55}, Shan Wang-Gohrke⁵⁶, Ursula Eilber²⁰, Thilo

URLs HapMap <http://hapmap.ncbi.nlm.nih.gov/>

Conflicts of interest The authors have no conflict competing financial interests to disclose.

Authors contribution M.G. and D.F.E. wrote the manuscript. K.M., M.G. and D.F.E. performed the statistical analysis. O.F., N.J., N.O., I.dosS.S., M.L. and J.P. led the BBCS GWAS. D.F.E., P.D.P.P., A.M.D., C.T. and N.R. led the UK2 GWAS. Q.Waisfisz and H.M.-H. led the DFBBGS GWAS, with support from A.G.U. and F.R.. P.Hall, K.C., A.I. and J.Liu led the SASBAC GWAS. H.N., K.A. and C.Blomqvist led the HEBGS GWAS. A.Meindl, R.K.S. and B.M.-M. led the GC-HBOC GWAS. J.C.-C., R.H., S.N. and D.F.-J. led the MARIE GWAS. J.L.H., M.Southey, H.T., E.M., D.S. and M.Bui led the ABCFS/kConFab GWAS. D.J.H. and S.J.C. led the CGEMS GWAS. E.D. and J.D. provided bioinformatics support. Q.Wang, M.K.H. and K.D. provided data management support for BCAC. C.Baynes, D.C., M.M. and S.A. managed centralised genotyping for BCAC samples. M.K.S. provided gene expression analysis. J.L.H., M.Southey, C.A. and D.J.P. co-ordinated the ABCFR study. M.K.S., A.B., S.V. and F.B.L.H. co-ordinated ABCS. P.A.F. co-ordinated the BBCC study. E.S., I.T. and M.K. co-ordinated BIGGS. F.Marme, ASchneeweiss, C.Sohn and B.Burwinkel co-ordinated the BSUCH study. P.G., T.T., E.C.-D. and F.Menegaux co-ordinated the CECILE study. S.E.B., B.G.M. and S.F.N. co-ordinated CGPS. R.L.M., R.A., A.G.-N. and J.Benítez co-ordinated CNIO-BCS. H.A.-C., A.Z., L.Bernstein and C.C.D. co-ordinated CTS. H.Brenner, H.M., V.A. and C.Stegmaier co-ordinated the ESTHER study. C.J., H.Brauch and B.P. co-ordinated the GENICA study. J.C.-C., S.W.-G. and U.E. co-ordinated the GESBC study. T.D., P.S., M.Bremer and P.Hillemanns co-ordinated HABCS. N.V.B., N.N.A., Y.I.R., J.H.K. and T.D. co-ordinated HMBCS. M.Bermisheva, D.P., N.V.B., T.D., and E.K. co-ordinated HUBCS. A.Lindblom and S.Margolin co-ordinated the KARBAC study. A.Mannermaa, V.Katja, V.-M.K. and J.M.H. co-ordinated the KBCP study. D.L., B.T.Y., G.F. and K.L. co-ordinated the LMBC study. S.Manoukian, B.Bonanni, S.F. and P.P. co-ordinated the MBCSG study. F.J.C., X.W., K.S. and A.Lee co-ordinated the MCBCS study. M.Southey, G.G.G., L.Baglietto, G.S. and C.M. co-ordinated MCCS. G.G.A., V.Kristensen and A.-L.B.-D. co-ordinated NBCS. E.M.J. and A.Miron co-ordinated the NC-BCFR study. R.W., K.P., A.J.-V. and S.K. co-ordinated OBCS. I.L.A., G.G. and A.M.M. co-ordinated the OFBCR study. P.D. C.J.vanA., R.A.E.M.T. and C.Seynaeve co-ordinated the ORIGO study. J.D.F., M.G.-C., L.Brinton and J.Lissowska co-ordinated PBCS. M.J.H., A.H., R.A.O. and A.M.W.v.d.O. co-ordinated RBCS. A.Cox and M.W.R.R. co-ordinated SBCS. B.A.P. initiated SEARCH with P.D.P.P. and D.F.E.. M.Shah co-ordinated SEARCH. A.J., J.Lubinski, K.J. and K.Durda co-ordinated SZBCS. M.J., M.Schoemaker, A.A. and A.Swerdlow co-ordinated UKBGS. G.C.-T. led the contribution of kConFab cases and AOCs controls to BCAC, J.Beasley and X.C. performed iPLEX genotyping for several of the BCAC sites. K.R.M., A.Lophatananon, S.R. and A.Chaiwerawattana co-ordinated the ACP study. D.K., K.-Y.Y. and D.-Y.N. co-ordinated SEBCS. C.-Y.S. J.-C.Y., P.-E.W. and C.-N.H. co-ordinated TWBCS. A.P., R.S. and L.V. co-ordinated DBCSS. D.M.E., W.J.T., S.M.G. and N.J.G. co-ordinated the POSH study.

Dörk⁵⁷, Peter Schürmann⁵⁷, Michael Bremer⁵⁷, Peter Hillemanns⁵⁷, Natalia V. Bogdanova⁵⁸, Natalia N. Antonenkova⁵⁹, Yuri I. Rogov⁵⁹, Johann H. Karstens⁵⁸, Marina Bermisheva⁶⁰, Darya Prokofieva⁶⁰, Elza Khusnutdinova⁶⁰, Annika Lindblom⁶¹, Sara Margolin⁶², Arto Mannermaa^{63,64,65}, Vesa Kataja^{64,66,67}, Veli-Matti Kosma^{63,64,65}, Jaana M Hartikainen^{63,64,65}, Diether Lambrechts⁶⁸, Betül T. Yesilyurt⁶⁸, Giuseppe Floris⁶⁹, Karin Leunen⁶⁹, Siranoush Manoukian⁷⁰, Bernardo Bonanni⁷¹, Stefano Fortuzzi⁷², Paolo Peterlongo⁷³, Fergus J Couch^{74,75}, Xianshu Wang⁷⁴, Kristen Stevens⁷⁵, Adam Lee⁷⁶, Graham G. Giles^{25,77}, Laura Baglietto^{25,77}, Gianluca Severi^{25,77}, Catriona McLean⁷⁸, Grethe Grenaker Alnæs⁷⁹, Vessela Kristensen^{79,80}, Anne-Lise Børresen-Dale^{79,80}, Esther M. John^{81,82}, Alexander Miron⁸³, Robert Winqvist⁸⁴, Katri Pylkäs⁸⁴, Arja Jukkola-Vuorinen⁸⁵, Salla Kauppila⁸⁶, Irene L. Andrulis^{87,88}, Gord Glendon⁸⁹, Anna Marie Mulligan^{90,91}, Peter Devilee^{92,93}, Christie J. van Asperen⁹⁴, Rob A.E.M. Tollenaar⁹⁵, Caroline Seynaeve⁹⁶, Jonine D Figueroa²⁷, Montserrat Garcia-Closas^{4,97}, Louise Brinton²⁷, Jolanta Lissowska⁹⁸, Maartje J. Hoening⁹⁹, Antoinette Hollestelle¹⁰⁰, Rogier A. Oldenburg¹⁰¹, Ans M.W. van den Ouweland¹⁰¹, Angela Cox¹⁰², Malcolm WR Reed¹⁰³, Mitul Shah¹, Ania Jakubowska¹⁰⁴, Jan Lubinski¹⁰⁴, Katarzyna Jaworska¹⁰⁴, Katarzyna Durda¹⁰⁴, Michael Jones⁹⁷, Minouk Schoemaker⁹⁷, Alan Ashworth², Anthony Swerdlow⁹⁷, Jonathan Beesley¹⁰⁵, Xiaoqing Chen¹⁰⁵, kConFab Investigators¹⁰⁶, Australian Ovarian Cancer Study Group¹⁰⁶, Kenneth R Muir¹⁰⁷, Artitaya Lophatananon¹⁰⁷, Suthee Rattanamongkongul¹⁰⁸, Arkom Chaiwerawattana¹⁰⁹, Daehee Kang¹¹⁰, Keun-Young Yoo¹¹⁰, Dong-Young Noh¹¹⁰, Chen-Yang Shen¹¹¹, Jyh-Cherng Yu¹¹², Pei-Ei Wu¹¹¹, Chia-Ni Hsiung¹¹¹, Annie Perkins¹¹³, Ruth Swann¹¹³, Louiza Velentzis¹¹³, Diana M Eccles¹¹⁴, Will J Tapper¹¹⁴, Susan M Gerty¹¹⁴, Nikki J Graham¹¹⁴, Bruce A. J. Ponder^{115,116}, Georgia Chenevix-Trench¹⁰⁵, Paul D.P. Pharoah^{1,3}, Mark Lathrop^{117,118}, Alison M. Dunning¹, Nazneen Rahman⁴, Julian Peto⁷, and Douglas F Easton^{1,3}

¹Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK ²Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK ³Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK ⁴Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK ⁵Department of Experimental Therapy, Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands ⁶Department of Epidemiology, Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands ⁷Non-communicable Disease Epidemiology Department, London School of Hygiene and Tropical Medicine, London, UK. ⁸Department of Clinical Genetics, VU University Medical Center, section Oncogenetics, Amsterdam, The Netherlands ⁹Department of Internal Medicine and Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands ¹⁰Netherlands Collaborative Group on Hereditary Breast and Ovarian Cancer ¹¹Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm 17177, Sweden ¹²Human Genetics Division, Genome Institute of Singapore, Singapore 138672, Singapore ¹³Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland ¹⁴Department of Clinical Genetics, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland ¹⁵Department of Oncology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland ¹⁶Clinic of Gynaecology and Obstetrics, Division for Gynaecological Tumor-Genetics, Technische Universität München, München, Germany ¹⁷Department of Obstetrics and Gynaecology, Division of Molecular Gynaeco-Oncology, University of Cologne, Germany ¹⁸Max Planck Institute of Psychiatry, Munich, Germany ¹⁹Institute of Human Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany ²⁰Division of Cancer Epidemiology, Deutsches Krebsforschungszentrum, Heidelberg, Germany ²¹PMV Research Group at the Department of Child and Adolescent Psychiatry and Psychotherapy, University of Cologne, Cologne, Germany ²²Department of Cancer Epidemiology/Clinical Cancer Registry, University Clinic Hamburg-Eppendorf, Hamburg, Germany ²³Institute for Medical Biometrics and

Epidemiology, University Clinic Hamburg-Eppendorf, Hamburg, Germany ²⁴Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Australia ²⁵Centre for Molecular, Environmental, Genetic, and Analytic Epidemiology, Melbourne School of Population Health, The University of Melbourne, Australia ²⁶Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA ²⁷Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA ²⁸Department of Clinical Genetics, Family Cancer Clinic, Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands ²⁹Department of Molecular Pathology, Family Cancer Clinic, Netherlands Cancer Institute, Antoni van Leeuwenhoek hospital, Amsterdam, The Netherlands ³⁰University Breast Center, Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany ³¹Institute of Human Genetics, Friedrich-Alexander University Erlangen Nuremberg, Erlangen, Germany ³²Division of Cancer Studies, NIHR Comprehensive Biomedical Research Centre, Guy's & St. Thomas' NHS Foundation Trust in partnership with King's College London, London, UK ³³Wellcome Trust Centre for Human Genetics and Oxford Biomedical Research Centre, University of Oxford, UK ³⁴Clinical Science Institute, University Hospital Galway, Galway, Ireland ³⁵Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg, Germany ³⁶National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany ³⁷Molecular Epidemiology Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany ³⁸Inserm, CESP Centre for research in Epidemiology and Population Health, U1018, Environmental epidemiology of cancer, Villejuif, France ³⁹Université Paris-Sud, UMRS 1018, Villejuif, France ⁴⁰Copenhagen General Population Study, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark ⁴¹Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark ⁴²Department of Breast Surgery, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark ⁴³Genetic & Molecular Epidemiology Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain ⁴⁴Human Genotyping Unit, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain ⁴⁵Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain ⁴⁶Department of Epidemiology, University of California Irvine, Irvine, California, USA ⁴⁷City of Hope Cancer Centre, Duarte, California, USA ⁴⁸Cancer Prevention Institute of California, Fremont, California, USA ⁴⁹Division of Clinical Epidemiology and Aging Research, German Cancer Research Center [DKFZ], Heidelberg, Germany ⁵⁰Saarland Cancer Registry, Saarbrücken, Germany ⁵¹Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart ⁵²University of Tübingen, Germany ⁵³Institute for Prevention and Occupational Medicine of the German Social Accident Insurance (IPA), Bochum, Germany ⁵⁴Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany ⁵⁵Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus, Bonn, Germany ⁵⁶Department of Obstetrics and Gynecology, University of Ulm, Ulm, Germany ⁵⁷Department of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany ⁵⁸Department of Radiation Oncology, Hannover Medical School, Hannover, Germany ⁵⁹N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus ⁶⁰Institute of Biochemistry and Genetics, Ufa Scientific Center of Russian Academy of Sciences, Ufa, Russia ⁶¹Department Molecular Medicine and Surgery, Karolinska Institutet, Stockholm ⁶²Department Onkologi-pathology, Karolinska Institutet, Stockholm ⁶³School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland ⁶⁴Biocenter Kuopio, Kuopio Finland ⁶⁵Department of Clinical Pathology, Kuopio University Hospital, Kuopio, Finland ⁶⁶School of Medicine, Institute of Clinical Medicine, Oncology, University of Eastern Finland, Kuopio, Finland ⁶⁷Department of Oncology, Kuopio University Hospital, Kuopio, Finland ⁶⁸Vesalius Research Center [VRC], VIB, Leuven, Belgium ⁶⁹Multidisciplinary Breast Center, University Hospital Gasthuisberg, Leuven, Belgium ⁷⁰Unit of Medical Genetics, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto

Nazionale Tumori (INT), Milan, Italy ⁷¹Division of Cancer Prevention and Genetics, Istituto Europeo di Oncologia (IEO), Milan, Italy ⁷²IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy ⁷³Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy and IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy ⁷⁴Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA ⁷⁵Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA ⁷⁶Department of Pharmacology, Mayo Clinic, Rochester, Minnesota, USA ⁷⁷Cancer Epidemiology Centre, The Cancer Council Victoria, Melbourne, Australia ⁷⁸Department of Anatomical Pathology, Alfred Hospital, Melbourne, Australia ⁷⁹Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway ⁸⁰Institute for Clinical Medicine, Faculty of Medicine, UiO, Norway ⁸¹Cancer Prevention Institute of California, Fremont, California, USA ⁸²Stanford University School of Medicine, Stanford, California, USA ⁸³Dana-Farber Cancer Institute, Boston, Massachusetts, USA ⁸⁴Laboratory of Cancer Genetics, Department of Clinical Genetics and Biocenter Oulu, University of Oulu, Oulu University Hospital, Oulu, Finland. ⁸⁵Department of Oncology, University of Oulu, Oulu University Hospital, Oulu, Finland. ⁸⁶Department of Pathology, University of Oulu, Oulu University Hospital, Oulu, Finland. ⁸⁷Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital ⁸⁸Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada ⁸⁹Ontario Cancer Genetics Network, Cancer Care Ontario, Toronto, Ontario, Canada ⁹⁰Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada ⁹¹Department of Laboratory Medicine, and the Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, Ontario, Canada ⁹²Department of Human Genetics, Leiden University Medical Centre, Leiden, The Netherlands ⁹³Department of Pathology, Leiden University Medical Centre, Leiden, The Netherlands ⁹⁴Department of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands ⁹⁵Department of Surgery, Leiden University Medical Centre, Leiden, The Netherlands ⁹⁶Department of Medical Oncology, Rotterdam Family Cancer Clinic, Erasmus MC-Daniel den Hoed Cancer Center, Rotterdam, The Netherlands ⁹⁷Section of Epidemiology, Institute of Cancer Research, Sutton, United Kingdom ⁹⁸Department of Cancer Epidemiology and Prevention, M. Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland ⁹⁹Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands ¹⁰⁰Department of Medical Oncology, Josephine Nefkens Institute, Erasmus University Medical Center, Rotterdam, The Netherlands ¹⁰¹Department of Clinical Genetics, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, The Netherlands ¹⁰²Institute for Cancer Studies, Department of Oncology, University of Sheffield, Sheffield, UK ¹⁰³Academic Unit of Surgical Oncology, Department of Oncology, University of Sheffield, Sheffield, UK ¹⁰⁴International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland ¹⁰⁵Queensland Institute of Medical Research, Brisbane, Australia ¹⁰⁶Peter MacCallum Cancer Center, Melbourne, Australia ¹⁰⁷Warwick Medical School, Warwick University, Coventry, UK ¹⁰⁸Department of Preventive Medicine, Srinakhrainwirot University, Ongkharak, Nakhon Nayok, Thailand ¹⁰⁹Department of Academic support, The National Cancer Institute of Thailand, Ministry of Public Health, Thailand ¹¹⁰Seoul National University College of Medicine, Seoul, Korea ¹¹¹Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan ¹¹²Department of Surgery, Tri-Service General Hospital, Taipei, Taiwan ¹¹³Against Breast Cancer Research Group, Department of Molecular and Applied Biosciences, University of Westminster, London, UK ¹¹⁴Faculty of Medicine, University of Southampton, Southampton, UK ¹¹⁵Department of Oncology, University of Cambridge, Cambridge, UK ¹¹⁶CRUK Cambridge Research Institute, Cambridge, UK ¹¹⁷Centre National de Genotypage, Evry, France. ¹¹⁸Fondation Jean Dausset – CEPH, Paris, France.

Abstract

Breast cancer is the most common cancer among women. To date, 22 common breast cancer susceptibility loci have been identified accounting for ~ 8% of the heritability of the disease. We followed up 72 promising associations from two independent Genome Wide Association Studies (GWAS) in ~70,000 cases and ~68,000 controls from 41 case-control studies and nine breast cancer GWAS. We identified three new breast cancer risk loci on 12p11 (rs10771399; $P=2.7 \times 10^{-35}$), 12q24 (rs1292011; $P=4.3 \times 10^{-19}$) and 21q21 (rs2823093; $P=1.1 \times 10^{-12}$). SNP rs10771399 was associated with similar relative risks for both estrogen receptor (ER)-negative and ER-positive breast cancer, whereas the other two loci were associated only with ER-positive disease. Two of the loci lie in regions that contain strong plausible candidate genes: *PTHLH* (12p11) plays a crucial role in mammary gland development and the establishment of bone metastasis in breast cancer, while *NR1P1* (21q21) encodes an ER co-factor and has a role in the regulation of breast cancer cell growth.

Breast cancer is one of the most commonly occurring epithelial malignancies in women with an estimated one million new cases and over 400,000 deaths annually worldwide¹. Familial aggregation and twin studies have demonstrated the substantial contribution of inherited susceptibility to breast cancer^{2,3}. Over the last four years, we and others have conducted several genome-wide association studies (GWAS) and reported breast cancer susceptibility variants at 21 loci⁴⁻¹⁴ with an additional locus (*CASP8*) identified through a candidate gene approach¹⁵. These variants are associated with modest risks of the disease (per-allele odds ratios <1.3), and explain ~ 8% of the excess familial risk of breast cancer, while other rarer high and moderate risk loci contribute less than 20%, suggesting that other loci remain to be identified¹⁶.

To identify further breast cancer susceptibility loci, we selected 72 SNPs that were genotyped and found to be significantly associated with breast cancer at $P < 0.0001$ in either of two breast cancer GWAS in the UK (UK2 and BBCS)^{17,18}. We attempted to genotype these SNPs in up to 41 case-control studies through the Breast Cancer Association Consortium (BCAC). After quality control (QC) exclusions (see Methods), we analysed data on 54,588 cases of invasive breast cancer, 2401 cases of Ductal Carcinoma *in Situ* (DCIS) and 58,098 controls. In addition, we utilised data from 7 additional breast cancer GWAS from which summary results had been obtained based on imputation to Hapmap 2 CEU. Results from the GWAS and BCAC replication were then combined to derive the overall evidence of association for each SNP based on 69,564 cases and 68,150 controls.

Three SNPs showed strong evidence for association in European women, consistent with the effect seen in the original GWAS (Table 1 and Figure 1). In each case, the genotype-specific odds ratios (ORs) were consistent with an allele dose (log-additive) model (Supplementary Table 1). SNP rs2823093 showed some evidence of heterogeneity in the per-allele ORs among studies in the replication stage ($P=0.002$), with particularly marked associations in two studies (HMBCS, RBCS; Figure 1). The association in the replication stage remained highly significant, however, even after excluding these two studies ($P=7.1 \times 10^{-7}$). The other two loci showed no evidence of heterogeneity among studies. Two additional SNPs on 17q21, rs2532348 and rs199523 (correlated at $r^2=0.80$ in the UK2 GWAS), gave more limited evidence of replication ($P=0.000078$ and $P=0.0063$) and reached $P=5.8 \times 10^{-7}$ and $P=2.6 \times 10^{-6}$ respectively when combined with the GWAS data (Supplementary Table 2). These SNPs were only genotyped in the UK2 GWAS. They could not be imputed using HapMap, and were only successfully genotyped in 12 studies in the BCAC replication. Moreover, for SNP rs2532348 there was evidence of heterogeneity among studies in the per-allele ORs in BCAC ($P=0.001$). Further data will be required to determine whether this SNP is associated with breast cancer risk. Three other SNPs (rs10940235 on 5q11, rs4403040 on

4q21 and rs6027564 on 20q13) showed evidence of replication at $P < 0.01$ but none reached genome-wide levels of statistical significance (Supplementary Table 2).

For women of Asian ancestry, SNP rs10771399 (12p11) was also associated with breast cancer risk, with the estimated OR being similar to that in women of European ancestry (Supplementary Table 3). There was no significant evidence of association for either SNPs rs1292011 (12q24) or rs2823093 (21q21) in women of Asian ancestry. For rs2823093, the estimated OR was in the opposite direction than that in women of European ancestry, but the estimates did not differ significantly (Supplementary Table 3).

SNP rs10771399 showed strong evidence of association with both estrogen receptor (ER)-positive and ER-negative breast cancer, with the estimated per-allele ORs being similar (based on 24,775 ER-positive and 7,122 ER-negative cases; Supplementary Table 4a). In contrast, for SNPs rs1292011 and rs2823093, the association was confined to ER-positive breast cancer, with no evidence of association for ER-negative disease (Supplementary Table 4a). These latter results conform to the general pattern of a preponderance of common susceptibility loci for ER-positive disease identified through GWAS based on cases unselected for disease subtype^{19, 20}. In terms of per-allele OR, SNP rs10771399 has one of the strongest effects identified to date for ER-negative breast cancer (OR 0.85, 95% CI 0.80-0.90). For all three SNPs, the per-allele OR for DCIS was similar to that for invasive disease (based on up to 2,148 DCIS cases; Supplementary Table 4b). For SNP rs10771399, the estimated OR was higher for 10 studies in which cases were selected for a positive family history and/or bilaterality, as would be expected under a polygenic model²¹ ($P = 0.027$, Supplementary Table 5); however, exclusion of data from these studies made little difference to the estimated OR. There was no evidence for difference in the per-allele OR by age at diagnosis for any SNP (Supplementary Table 4c).

SNP rs10771399 lies in a ~300kb linkage disequilibrium (LD) block on 12p11 that contains one known gene, *PTH1L* (Parathyroid Hormone like Hormone isoform 1), also called *PTHrP* (Parathyroid hormone-related protein; Figure 2a). PTHrP is expressed in a wide variety of tissues and in many malignancies, including 60% of breast tumors and is required for normal mammary gland and bone development²²⁻²⁵. During lactation it is released by the mammary gland to regulate the transfer of calcium from the skeleton to the milk^{26, 27}. Tumor secreted PTHrP mimics the action of parathyroid hormone (PTH) by binding to its receptor PTH1R²⁸ promoting humoral hypercalcemia as well as metastasis of breast cancer cells to the bone^{23, 29-31}. It has been suggested that PTHrP enhances tumorigenesis through its pro-proliferative and anti-apoptotic activity by promoting survival in cells subjected to apoptosis^{32, 33}. However, conflicting data regarding the correlation of PTHrP expression level and breast cancer survival have been found^{24, 34-36}. Moreover, a recent study reported that loss of PTHrP accelerates tumor incidence in DCIS and is associated with monocyte infiltration³⁷.

SNP rs1292011 on 12q24 lies in a ~ 100 kb LD block that contains no known genes (Figure 2b). SNPs in this region have been found to be associated with squamous esophageal carcinoma, renal cell carcinoma, liver adenoma, heart disease and type 1 diabetes as well as blood pressure and PSA levels³⁸⁻⁴⁷. Two plausible cancer candidate genes, *MAPKAPK5* (mitogen-activated protein kinase-activated protein kinase 5, also called *MK5/PRAK*) and *TBX3* (T-box3), lie within 2 Mb of rs1292011. *MAPKAPK5* is a member of the serine/threonine kinase family and is directly activated by *Myc*⁴⁸. *TBX3* plays a role in mammary gland development⁴⁹ and its haplo-insufficiency is associated with Ulnar-Mammary disorder⁵⁰. *TBX3* was found to be amplified and over-expressed in several cancers including breast cancer⁵¹⁻⁵⁴ and at high levels in plasma from breast and ovarian cancer patients⁵². Recently, it has been shown that estrogen regulates the expansion of breast cancer stem cells

through the FGF/FGFR/TBX3 pathway^{52, 55} and that *TBX3* is a direct downstream target of the Wnt/beta-catenin pathway⁵⁶. The expression of *TBX3* was found to be significantly higher ($P < 0.0001$) in ER-positive than in ER-negative breast cancer tumors in two independent datasets containing 781 tumors (with HGU-133A Affymetrix expression data)⁵⁷ and 244 tumors (with 44k Agilent expression data)⁵⁸. These data suggest that the association of rs1292011 with ER-positive breast cancer could be mediated through its effect on *TBX3*.

SNP rs2823093 lies in a ~ 130 Kb LD block containing no known genes. The nearest gene, ~900 Kb downstream, is *NRIP1* (Nuclear Receptor interacting protein 1) (Figure 2 c) or also called *RIP140* (Receptor-interacting protein 140). RIP140 acts as a strong transcriptional repressor for nuclear receptors^{59, 60}. It interacts with estrogen receptor α (ER α), represses the ER signalling and inhibits its mitogenic effects⁶¹. This repression is mediated through interaction with FHL1, a protein involved in suppressing cancer cell growth and migration⁶². Several lines of evidence suggest that RIP140 plays an important role in the regulation of breast cancer cell growth. Knockdown of *RIP140* was found to induce growth promotion in an ER-positive breast cancer cell line⁶¹. This protein was also highly induced following the treatment of human breast cancer cells with retinoids, known for their breast cancer growth suppression and their anti-estrogenic effects⁶³⁻⁶⁶. A Spanish case-control study, which genotyped SNPs in 91 breast cancer candidate genes in ~700 cases and ~700 controls, identified a relatively rare SNP at this locus (rs926184 - MAF~2%), located 175 Kb upstream of rs2823093, which showed a modest association with breast cancer⁶⁷. These two SNPs are, however, not correlated ($r^2=0$ in HapMap CEU). The expression of *NRIP1* has been shown to be significantly higher in ER-positive than ER-negative tumors ($p < 0.0001$)^{57, 58} suggesting that the association of rs2823093 with ER-positive breast cancer could be mediated through its effect on *NRIP1* expression^{57, 58}.

The three novel susceptibility variants identified in this study are relatively common (MAF 0.11-0.41) and together explain ~0.7% of the familial risk of breast cancer, and bring the total contribution of common low-penetrance breast cancer susceptibility loci to ~9%. The relative risks associated with these variants are modest, with the per-allele ORs for the risk allele ranging from 1.07 to 1.22 fold, but the causal variants underlying some of these loci might confer more substantial risks. The present work highlights the importance of combining GWAS and large-scale replication studies with tumor subtyping in the identification and characterisation of breast cancer susceptibility loci.

The genes in these regions (if proven to be the causal genes) underscore that diverse mechanisms are likely to be relevant to breast cancer pathogenesis. Re-sequencing of these loci, combined with fine-scale mapping and functional analyses will provide more insights into the genetic architecture of breast cancer and the pathogenesis of the disease.

Methods

GWAS analysis

Primary genotype data were obtained for nine breast cancer GWAS in populations of European ancestry (Supplementary Table 6). Standard QC was performed on all scans, as follows. We excluded all individuals with low call rate ($< 95\%$), extreme high or low heterozygosity ($P < 10^{-5}$), and all individuals evaluated to be of non-European ancestry ($> 15\%$ non-European component, by multidimensional scaling using the three Hapmap2 populations as a reference). We excluded SNPs with: call rate $< 95\%$; call rate $< 99\%$ and MAF $< 5\%$, all SNPs with MAF $< 1\%$, and SNPs whose genotype frequencies departed from Hardy-Weinberg equilibrium at $P < 10^{-6}$ in controls or $P < 10^{-12}$ in cases. For highly

significant SNPs the genotype intensity cluster plots were examined manually to judge reliability, either centrally or by contacting the original investigators.

Data were imputed for all scans for ~2.6M SNPs using HapMap version 2 CEU as a reference, using the program Mach v1.0. Estimated per-allele ORs and standard errors were generated from the imputed genotypes using ProbABEL⁶⁹. For two studies (UK2 and HEBCS), estimates were adjusted by the first three principal components, since this was found to materially reduce the inflation. Residual inflation was then adjusted for by multiplying the variance by a genomic control adjustment factor, based on the ratio of the median chi-squared test statistic to its expected value. BBCS and UK2 used the same control data (WTCCC2) but different genotyping platforms. These studies were imputed separately. For the combined analysis, the control set was divided randomly between the two studies, in proportion to the size of case series, to provide disjoint strata. For a limited subset of SNPs that could not be imputed (including rs2532348 and rs199523 on 17q21), genotype data from the original scan(s) were used in the analysis.

Replication stage

SNPs for replication were genotyped in 46 studies, of which 4 were case-only studies that did not contribute to the current analysis (Supplementary Table 7). Data from BBCS were excluded as the same cases were included in the GWAS. Seven studies (HABCS, HMBCS, HUBCS, KARBAC, RBCS, SEARCH and SEBCS) were analysed by Fluidigm for 72 SNPs (Supplementary Table 2). We selected 63 SNPs selected from UK2: one replaced by a better surrogate, and one failed, so only data were available for 61 SNPs. Ten SNPs were selected from BBCS and one SNP was selected from both scans (The original SNP, rs1975930, also referred to as rs56003999, did not work by Fluidigm and in some iPlex analyses and was replaced by a surrogate rs10771399, $r^2=0.95$, which was typed in all studies). Samples from 27 studies were genotyped by iPlex for 29 SNPs that showed the strongest associations. Seven additional studies (ABCFS, CGPS, MCCS, NC-BCFR, OFBCR, PBCS, UKBGS) were genotyped by Taqman for up to 4 SNPs that showed association after the Fluidigm and iPlex genotyping, including all three 3 SNPs discussed in detail here. We restricted the analysis to individuals of European or East Asian ancestry, since the sample size for other ethnicities was too small to give meaningful results.

All studies complied with BCAC genotyping QC standards by including at least 2% of samples in duplicate and a common set of 93 CEPH DNAs used by the HapMap Consortium (HAPMAPPT01, Coriell Institute for Medical Research, Cambden, NJ). Genotype data were excluded for: any sample that consistently failed genotyping for >20% of the SNPs typed; all samples on any one plate that had a SNP call rate <90%; all genotype data for any SNP where overall call rate was <95%; and all genotype data for any SNP where duplicate concordance was <98% (based on 2% of samples genotyped in duplicate). In addition, for any SNP for which the P -value for departure from Hardy-Weinberg equilibrium for controls was <0.005, clustering of the intensity plots was reviewed manually and the data excluded if clustering was judged to be poor. After QC exclusions we analysed data on 54,588 cases of invasive breast cancer, 2,401 cases of DCIS and 58,098 controls.

Per-allele and genotype-specific odds ratios for the replication stage were estimated using logistic regression, adjusted for study. Women of European and Asian ancestry were analysed separately. NC-BCFR contributed cases and controls to both European and Asian analyses; for the remaining studies the subjects were either predominantly European or predominantly Asian, and subjects from other minority ethnicities were excluded.

Statistical significance levels from the GWAS and BCAC replication phases were obtained by combining the logOR estimates and standard errors as in a fixed effect meta-analysis.

Heterogeneity in the OR association with each SNP by ER status was evaluated using a case-only analysis, by logistic regression. Heterogeneity by age was evaluated by fitting a linear age \times genotype interaction term.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We would thank the following individuals for their contribution to this project (study in brackets): Sten Cornelissen, Richard van Hien, Linde Braaf, Laura Van't Veer, Bas Bueno-de-Mesquita and Sander Canisius (ABCS); Niall McInerney, Gabrielle Colleran, Andrew Rowan and Nicola Miller (BIGGS); Anne Langheinz (BSUCH); José Ignacio Arias Pérez, Pilar Zamora, Primitiva Menendez, Tais Moreno and Guillermo Pita (CNIO-BCS); Muriel Adank, Margreet Ausems and Senno Verhoef (DFBBCS); Ute Hamann, Yon-Dschun Ko, Christian Baisch, Hans-Peter Fischer, Beate Pesch, Sylvia Rabstein and Volker Harth (GENICA); Kirsimari Aaltonen, Päivi Heikkilä, Tuomas Heikkinen, Dario Greco, RN Hanna Jäntti and Irja Erkkilä (HEBCS); Helena Kemiläinen, Eija Myöhänen and Aija Parkkinen (KBCP); Tracy Slanger, Elke Mutschelknauss, S. Behrens, R. Birr, M.Celik, U. Eilber, B. Kaspereit, N. Knese and K. Smit (MARIE); Paolo Radice, Bernard Peissel, Monica Barile, Marco A. Pierotti (MBCSG); Teresa Selander, Mona Gill, Lucine Collins and Nayana Weerasooriya (OFBCR); Mervi Grip, Kari Mononen and Meer Otsukka (OBCS); E. Krol-Warmerdam, and J. Blom (ORIGO); Dr. Prat Boonyawongviroj and Dr. Pornthep Siriwanarungsan (ACP). For full acknowledgements including funding see Supplementary Note.

Reference List

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol*. 2006; 24:2137–2150. [PubMed: 16682732]
2. Lichtenstein P, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med*. 2000; 343:78–85. [PubMed: 10891514]
3. Peto J, Mack TM. High constant incidence in twins and other relatives of women with breast cancer. *Nat Genet*. 2000; 26:411–414. [PubMed: 11101836]
4. Ahmed S, et al. Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nat Genet*. 2009; 41:585–590. [PubMed: 19330027]
5. Antoniou AC, et al. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet*. 2010; 42:885–892. [PubMed: 20852631]
6. Easton DF, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. *Nature*. 2007; 447:1087–1093. [PubMed: 17529967]
7. Fletcher O, et al. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. *J Natl Cancer Inst*. 2011; 103:425–435. [PubMed: 21263130]
8. Haiman CA, et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. *Nat Genet*. 2011
9. Hunter DJ, et al. A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. *Nat Genet*. 2007; 39:870–874. [PubMed: 17529973]
10. Stacey SN, et al. Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet*. 2007; 39:865–869. [PubMed: 17529974]
11. Stacey SN, et al. Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. *Nat Genet*. 2008; 40:703–706. [PubMed: 18438407]
12. Thomas G, et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). *Nat Genet*. 2009; 41:579–584. [PubMed: 19330030]
13. Turnbull C, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. *Nat Genet*. 2010; 42:504–507. [PubMed: 20453838]

14. Zheng W, et al. Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. *Nat Genet.* 2009; 41:324–328. [PubMed: 19219042]
15. Cox A, et al. A common coding variant in CASP8 is associated with breast cancer risk. *Nat Genet.* 2007; 39:352–358. [PubMed: 17293864]
16. Varghese JS, Easton DF. Genome-wide association studies in common cancers--what have we learnt? *Curr Opin. Genet Dev.* 2010; 20:201–209. [PubMed: 20418093]
17. Fletcher O, et al. Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study. *J Natl Cancer Inst.* 2011; 103:425–435. [PubMed: 21263130]
18. Turnbull C, et al. Genome-wide association study identifies five new breast cancer susceptibility loci. *Nat Genet.* 2010; 42:504–507. [PubMed: 20453838]
19. Broeks A, et al. Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. *Hum Mol Genet.* 2011; 20:3289–3303. [PubMed: 21596841]
20. Garcia-Closas M, et al. Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. *PLoS Genet.* 2008; 4:e1000054. [PubMed: 18437204]
21. Antoniou AC, Easton DF. Risk prediction models for familial breast cancer. *Future Oncol.* 2006; 2:257–274. [PubMed: 16563094]
22. Dunbar ME, Wysolmerski JJ, Broadus AE. Parathyroid hormone-related protein: from hypercalcemia of malignancy to developmental regulatory molecule. *Am J Med Sci.* 1996; 312:287–294. [PubMed: 8969618]
23. Philbrick WM, et al. Defining the roles of parathyroid hormone-related protein in normal physiology. *Physiol Rev.* 1996; 76:127–173. [PubMed: 8592727]
24. Southby J, et al. Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. *Cancer Res.* 1990; 50:7710–7716. [PubMed: 2253214]
25. Wysolmerski JJ, Stewart AF. The physiology of parathyroid hormone-related protein: an emerging role as a developmental factor. *Annu. Rev Physiol.* 1998; 60:431–460. [PubMed: 9558472]
26. Kovacs CS, Kronenberg HM. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. *Endocr Rev.* 1997; 18:832–872. [PubMed: 9408745]
27. Wysolmerski JJ. Interactions between breast, bone, and brain regulate mineral and skeletal metabolism during lactation. *Ann N Y. Acad Sci.* 2010; 1192:161–169. [PubMed: 20392232]
28. Juppner H, et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. *Science.* 1991; 254:1024–1026. [PubMed: 1658941]
29. DeMauro S, Wysolmerski J. Hypercalcemia in breast cancer: an echo of bone mobilization during lactation? *J Mammary. Gland. Biol Neoplasia.* 2005; 10:157–167. [PubMed: 16025222]
30. Dunbar ME, Wysolmerski JJ. Parathyroid hormone-related protein: a developmental regulatory molecule necessary for mammary gland development. *J Mammary. Gland. Biol Neoplasia.* 1999; 4:21–34. [PubMed: 10219904]
31. Wysolmerski JJ, Broadus AE. Hypercalcemia of malignancy: the central role of parathyroid hormone-related protein. *Annu. Rev Med.* 1994; 45:189–200. [PubMed: 8198376]
32. Henderson JE, et al. Nucleolar localization of parathyroid hormone-related peptide enhances survival of chondrocytes under conditions that promote apoptotic cell death. *Mol Cell Biol.* 1995; 15:4064–4075. [PubMed: 7623802]
33. Okoumassoun LE, Russo C, Denizau F, Averill-Bates D, Henderson JE. Parathyroid hormone-related protein (PTHrP) inhibits mitochondrial-dependent apoptosis through CK2. *J Cell Physiol.* 2007; 212:591–599. [PubMed: 17443683]
34. Henderson MA, et al. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. *Cancer Res.* 2006; 66:2250–2256. [PubMed: 16489028]
35. Linforth R, et al. Coexpression of parathyroid hormone related protein and its receptor in early breast cancer predicts poor patient survival. *Clin Cancer Res.* 2002; 8:3172–3177. [PubMed: 12374685]
36. Yoshida A, et al. Significance of the parathyroid hormone-related protein expression in breast carcinoma. *Breast Cancer.* 2000; 7:215–220. [PubMed: 11029801]

37. Fleming NI, et al. Parathyroid hormone-related protein protects against mammary tumor emergence and is associated with monocyte infiltration in ductal carcinoma in situ. *Cancer Res.* 2009; 69:7473–7479. [PubMed: 19723659]
38. Bluteau O, et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. *Nat Genet.* 2002; 32:312–315. [PubMed: 12355088]
39. Cho YS, et al. A large-scale genome-wide association study of Asian populations uncovers genetic factors influencing eight quantitative traits. *Nat Genet.* 2009; 41:527–534. [PubMed: 19396169]
40. Cui R, et al. Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. *Gastroenterology.* 2009; 137:1768–1775. [PubMed: 19698717]
41. Erdmann J, et al. New susceptibility locus for coronary artery disease on chromosome 3q22.3. *Nat Genet.* 2009; 41:280–282. [PubMed: 19198612]
42. Gudbjartsson DF, et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. *Nat Genet.* 2009; 41:342–347. [PubMed: 19198610]
43. Kato N, et al. Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. *Nat Genet.* 2011; 43:531–538. [PubMed: 21572416]
44. Purdue MP, et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. *Nat Genet.* 2011; 43:60–65. [PubMed: 21131975]
45. Soranzo N, et al. A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. *Nat Genet.* 2009; 41:1182–1190. [PubMed: 19820697]
46. Todd JA, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. *Nat Genet.* 2007; 39:857–864. [PubMed: 17554260]
47. Wu C, et al. Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. *Nat Genet.* 2011; 43:679–684. [PubMed: 21642993]
48. Kress TR, et al. The MK5/PRAK kinase and Myc form a negative feedback loop that is disrupted during colorectal tumorigenesis. *Mol Cell.* 2011; 41:445–457. [PubMed: 21329882]
49. Davenport TG, Jerome-Majewska LA, Papaioannou VE. Mammary gland, limb and yolk sac defects in mice lacking Tbx3, the gene mutated in human ulnar mammary syndrome. *Development.* 2003; 130:2263–2273. [PubMed: 12668638]
50. Bamshad M, et al. Mutations in human TBX3 alter limb, apocrine and genital development in ulnar-mammary syndrome. *Nat Genet.* 1997; 16:311–315. [PubMed: 9207801]
51. Fan W, Huang X, Chen C, Gray J, Huang T. TBX3 and its isoform TBX3+2a are functionally distinctive in inhibition of senescence and are overexpressed in a subset of breast cancer cell lines. *Cancer Res.* 2004; 64:5132–5139. [PubMed: 15289316]
52. Lomnytska M, Dubrovskaya A, Hellman U, Volodko N, Souchelnytskyi S. Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients. *Int J Cancer.* 2006; 118:412–421. [PubMed: 16049973]
53. Lyng H, et al. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. *BMC Genomics.* 2006; 7:268. [PubMed: 17054779]
54. Rowley M, Grothey E, Couch FJ. The role of Tbx2 and Tbx3 in mammary development and tumorigenesis. *J Mammary. Gland. Biol Neoplasia.* 2004; 9:109–118. [PubMed: 15300007]
55. Fillmore CM, et al. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. *Proc. Natl Acad Sci U. S. A.* 2010; 107:21737–21742. [PubMed: 21098263]
56. Renard CA, et al. Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer. *Cancer Res.* 2007; 67:901–910. [PubMed: 17283120]
57. Reyat F, et al. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. *Breast Cancer Res.* 2008; 10:R93. [PubMed: 19014521]
58. van de Vijver MJ, et al. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med.* 2002; 347:1999–2009. [PubMed: 12490681]

59. L'Horsset F, Dauvois S, Heery DM, Cavailles V, Parker MG. RIP-140 interacts with multiple nuclear receptors by means of two distinct sites. *Mol Cell Biol.* 1996; 16:6029–6036. [PubMed: 8887632]
60. Tazawa H, et al. Regulation of subnuclear localization is associated with a mechanism for nuclear receptor corepression by RIP140. *Mol Cell Biol.* 2003; 23:4187–4198. [PubMed: 12773562]
61. White KA, Yore MM, Deng D, Spinella MJ. Limiting effects of RIP140 in estrogen signaling: potential mediation of anti-estrogenic effects of retinoic acid. *J Biol Chem.* 2005; 280:7829–7835. [PubMed: 15632153]
62. Lin J, et al. Four and a half LIM domains 1 (FHL1) and receptor interacting protein of 140kDa (RIP140) interact and cooperate in estrogen signaling. *Int J Biochem. Cell Biol.* 2009; 41:1613–1618. [PubMed: 19401155]
63. Kerley JS, Olsen SL, Freemantle SJ, Spinella MJ. Transcriptional activation of the nuclear receptor corepressor RIP140 by retinoic acid: a potential negative-feedback regulatory mechanism. *Biochem. Biophys. Res Commun.* 2001; 285:969–975. [PubMed: 11467847]
64. White KA, et al. Negative feedback at the level of nuclear receptor coregulation. Self-limitation of retinoid signaling by RIP140. *J Biol Chem.* 2003; 278:43889–43892. [PubMed: 14506269]
65. Demirpence E, et al. Antiestrogenic effects of all-trans-retinoic acid and 1,25-dihydroxyvitamin D3 in breast cancer cells occur at the estrogen response element level but through different molecular mechanisms. *Cancer Res.* 1994; 54:1458–1464. [PubMed: 8137248]
66. Fontana JA, Nervi C, Shao ZM, Jetten AM. Retinoid antagonism of estrogen-responsive transforming growth factor alpha and pS2 gene expression in breast carcinoma cells. *Cancer Res.* 1992; 52:3938–3945. [PubMed: 1319834]
67. Vega A, et al. Evaluating new candidate SNPs as low penetrance risk factors in sporadic breast cancer: a two-stage Spanish case-control study. *Gynecol. Oncol.* 2009; 112:210–214. [PubMed: 18950845]
68. Johnson AD, et al. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. *Bioinformatics.* 2008; 24:2938–2939. [PubMed: 18974171]
69. Aulchenko YS, Struchalin MV, van Duijn CM. ProbABEL package for genome-wide association analysis of imputed data. *BMC Bioinformatics.* 2010; 11:134. [PubMed: 20233392]





Figure 1. Forest plots for the 3 SNPs showing evidence of association with breast cancer. Squares represent the estimated per-allele odds ratio (OR) for individual studies. The area of square is inversely proportional to the precise of the estimate. Diamonds represent the summary OR estimates for the subgroups indicated. Horizontal lines represent 95% confidence limits.



Figures 2a, b and c.

Association plots for the three new breast cancer susceptibility loci at (a) 12p11 (b) 12q24 and (c) 21q21 drawn using the SNAP software^{35, 68}. Genotyped and imputed SNPs are plotted based on their chromosomal position in build 36 on the X axis and their overall P values (as $-\log_{10}$ values) from the UK2 and BBCS GWAS on the Y axis. For each region, the most strongly associated SNP is represented by a diamond. The intensity of the red shading reflects the strength of correlation (r^2) between the best SNP and the other SNPs in the region. Genes present in the region (if any) are indicated in green.

Table 1

SNP	Chromosome Position ¹	Alleles ²	MAF	Stage	Per-allele OR (95%CI) ³	P	Combined P
rs10771399	12p11 28046347	AG	0.12	UK2	0.79 (0.71-0.87)	3.1×10 ⁻⁶	
			0.11	BBCS	0.84 (0.74-0.96)	.008	
			0.10	Other GWAS	0.83 (0.75-0.91)	5.7×10 ⁻⁵	
			0.12	BCAC replication	0.85 (0.83-0.88)	3.3×10 ⁻²⁷	2.7×10 ⁻³⁵
rs1292011	12q24 114320905	AG	0.41	UK2	0.88 (0.83-0.94)	5.8×10 ⁻⁵	
			0.42	BBCS	0.95 (0.88-1.03)	0.23	
			0.40	Other GWAS	0.91 (0.86-0.96)	.0008	
			0.41	BCAC replication	0.92 (0.91-0.94)	6.2×10 ⁻¹⁴	4.3×10 ⁻¹⁹
rs2823093	21q21 15442703	GA	0.26	UK2	0.96 (0.89-1.03)	0.21	
			0.26	BBCS	0.88 (0.76-0.92)	.00013	
			0.26	Other GWAS	0.91 (0.85-0.97)	.0032	
			0.27	BCAC replication	0.94 (0.92-0.96)	1.7×10 ⁻⁹	1.1×10 ⁻¹²

¹Build 36

²Minor allele listed second

³Per copy of the minor allele